Identification of Scores Associated With a Favorable Clinical Response With Thiopurines in IBD Patients (SCORE1)
Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial
Sponsor: Apsen Farmaceutica S.A.
Listed as NCT02367326, this observational or N/A phase trial focuses on Inflammatory Bowel Diseases and remains completed. Sponsored by Apsen Farmaceutica S.A., it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Jan 2017 — Sep 2017 [monthly]
Recruiting NA
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Apsen Farmaceutica S.A.
- Centre Hospitalier Universitaire de Saint Etienne
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Besançon, France , Caen, France , Dijon, France , Lilles, France , Montpellier, France , Nancy, France , Nantes, France , Nice, France , Orléans, France , Paris, France and 5 more locations